Recently Published Hep C Studies, Articles, and Press Releases

Recently Published Hep C Studies, Articles, and Press ReleasesThe following highlights a variety of recently published studies, articles, and press releases published about hepatitis C and hepatitis C treatments.

The American Association for the Study of Liver Diseases, Infectious Diseases Society of America, and International Antiviral Society-USA Hepatitis C Guidance Update (July 2016)

Summary: This version of guidance for those prescribing hepatitis C treatments was updated to included recent developments, such as the approval of the hepatitis C treatment Epclusa (sofosbuvir/velpatasvir).

Annals of Internal Medicine (August 2016)

Summary: The study evaluated Zepatier (elbasvir/grazoprevir) in treating hep C in those who inject drugs (PWID) while being treated for opioid use with opioid-agonist therapy (OAT). The study resulted in high rates of SVR12/’cure rates’ and low levels of side effects, regardless of ongoing drug use. ( blog post with more information)

Journal of Addiction Medicine (July/August 2016)

Summary:  Using population estimates, the assessment found 23 certifed physicians for every 1000 affected individuals. The study highlighted the need for more healthcare provider training for rural health regions. (CBC post with more information)

Journal of Hepatology (July/August 2016)

Summary: This head-2-head study compared the safety and efficacy of Zepatier (elbasvir/grazoprevir) and Sovaldi (sofosbuvir)  plus pegylated interferon/ribavirin (PR) in patients with hep C who were mainly treatment-naive, without liver cirrhosis, and had hep C genotype 1b. The study found that the SVR12/cure rates were 99.2% (Zepatier) and 90.5% (Sovaldi/PR). Both treatments only caused very low rates of side effects.

The Lancet Gastroenterology & Hepatology (August 2016)

Summary: This is an assessment of patient outcomes looking only at patient-reported outcomes (PROs) by patients with liver cirrhosis who took Epclusa (sofosbuvir and velpatasvir) with and without ribavirin. The study found that PROs, such as emotional, mental, and social well-being as well as work productivity, dipped during the hep C treatment but improved after it.

Summary:  In this proof-of-concept study, patients were give hep C treatments (sofosbuvir, ledipasvir, and asunaprevir; sofosbuvir, daclatasvir, and simeprevir; and sofosbuvir, daclatasvir, and asunaprevir) for only 3 weeks instead of the usual 12 or 24 weeks. The treatments were successful.

Recent Press Releases by Pharmaceutical Companies